This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
O'Donnell PH , Alanee S , Stratton KL , Garcia-Grossman IR , Cao H , Ostrovnaya I , Plimack ER , Manschreck C , Ganshert C , Smith ND , Steinberg GD , Vijai J , Offit K , Stadler WM , Bajorin DF
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer
Clin Genitourin Cancer. 2016 Dec;14(6) :511-517
PMID: 27150640 PMCID: PMC5018246 URL: http://www.ncbi.nlm.nih.gov/pubmed/27150640
AbstractBACKGROUND: Level 1 evidence has demonstrated increased overall survival with cisplatin-based neoadjuvant chemotherapy for patients with muscle-invasive urothelial cancer. Usage remains low, however, in part because neoadjuvant chemotherapy will not be effective for every patient. To identify the patients most likely to benefit, we evaluated germline pharmacogenomic markers for association with neoadjuvant chemotherapy sensitivity in 2 large cohorts of patients with urothelial cancer. PATIENTS AND METHODS: Patients receiving neoadjuvant cisplatin-based chemotherapy for muscle-invasive urothelial cancer were eligible. Nine germline single nucleotide polymorphisms (SNPs) potentially conferring platinum sensitivity were tested for an association with a complete pathologic response to neoadjuvant chemotherapy (pT0) or elimination of muscle-invasive cancer (<pT2). RESULTS: The data from 205 patients were analyzed-59 patients were included in the discovery set and 146 in an independent replication cohort-from 3 institutions. The stage pT0 (26%) and < pT2 (50%) rates were consistent across the discovery and replication populations. Using a multivariate recessive genetic model, rs244898 in RARS (odds ratio, 6.8; 95% confidence interval, 1.8-28.9; P = .006) and rs7937567 in GALNTL4 (odds ratio, 4.8; 95% confidence interval, 1.1-22.6; P = .04) were associated with pT0 in the discovery set. Despite these large effects, neither were associated with achievement of pT0 in the replication set. A third SNP, rs10964552, was associated with stage < pT2 in the discovery set but also failed to replicate. CONCLUSION: Germline SNPs previously associated with platinum sensitivity were not associated with the neoadjuvant chemotherapy response in a large replication cohort of patients with urothelial cancer. These results emphasize the need for replication when evaluating pharmacogenomic markers and demonstrate that multi-institutional efforts are feasible and will be necessary to achieve advances in urothelial cancer pharmacogenomics.
NotesO'Donnell, Peter H Alanee, Shaheen Stratton, Kelly L Garcia-Grossman, Ilana R Cao, Hongyuan Ostrovnaya, Irina Plimack, Elizabeth R Manschreck, Christopher Ganshert, Cory Smith, Norm D Steinberg, Gary D Vijai, Joseph Offit, Kenneth Stadler, Walter M Bajorin, Dean F ENG K12 CA139160/CA/NCI NIH HHS/ 2016/05/07 06:00 Clin Genitourin Cancer. 2016 Mar 10. pii: S1558-7673(16)30060-X. doi: 10.1016/j.clgc.2016.03.006.